// App-Quantinova.ai

PB1768 : IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS

Researchers

Presenter

  • Jack T Seki

Principal Investigators

  • Eshetu Atenafu

  • Hassan Sibai

Medical Centers

  • Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network,Toronto,Канада

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada

  • Leslie Dan Faculty of Pharmacy, ,University of Toronto,Toronto,Канада

  • Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Asparaginase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved